4.6 Article

RNA Exosome Complex Regulates Stability of the Hepatitis B Virus X-mRNA Transcript in a Non-stop-mediated (NSD) RNA Quality Control Mechanism

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 291, Issue 31, Pages 15958-15974

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M116.724641

Keywords

-

Funding

  1. Research Program on Hepatitis from the Japan Agency for Medical Research and development (AMED) Japan
  2. Miyakawa memorial research fund
  3. Grants-in-Aid for Scientific Research [15K15293] Funding Source: KAKEN

Ask authors/readers for more resources

Hepatitis B virus (HBV) is a stealth virus, minimally inducing the interferon system required for efficient induction of both innate and adaptive immune responses. However, 90% of acutely infected adults can clear the virus, suggesting the presence of other, interferon-independent pathways leading to viral clearance. Given the known ability of helicases to bind viral nucleic acids, we performed a functional screening assay to identify helicases that regulate HBV replication. We identified the superkiller viralicidic activity 2-like (SKIV2L) RNA helicase (a homolog of the Saccharomyces cerevisiae Ski2 protein) on the basis of its direct and preferential interaction with HBV X-mRNA. This interaction was essential for HBVX-mRNA degradation at the RNA exosome. The degradation of HBV X-mRNA at the RNA exosome was also mediated by HBS1L (HBS1-like translational GTPase) protein, a known component of the host RNA quality control system. We found that the redundant HBV-precore translation initiation site present at the 3'-end of HBV X-mRNA (3'precore) is translationally active. The initiation of translation from this site without a proper stop codon was identified by the non-stop-mediated RNA decay mechanism leading to its degradation. Although 3'-precore is present in the five main HBV-RNA transcripts, only X-mRNA lacks the presence of an upstream start codons for large, middle, and small (L, M, and S) HBV surface proteins. These upstream codons are in-frame with 3'-precore translation initiation site, blocking its translation from the other HBV-mRNA transcripts. To our knowledge, this is the first demonstration of the anti-viral function of the non-stop-mediated RNA decay mechanism.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Surgery

Risk Factors for Hepatocellular Carcinoma After Splenectomy in Liver Cirrhotic Patients

Naruhiko Honmyo, Tsuyoshi Kobayashi, Shintaro Kuroda, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Hiroshi Morimoto, Naoki Tanimine, Michinori Hamaoka, Megumi Yamaguchi, Masateru Yamamoto, Daisuke Takei, Hiroshi Aikata, Kazuaki Chayama, Hideki Ohdan

Summary: This study identified risk factors for hepatocellular carcinoma (HCC) development after splenectomy for portal hypertension. The etiology of cirrhosis, presence of HCC history, and preoperative hemoglobin level were found to be associated with HCC development. The predictive model constructed in this study may assist in surveillance for HCC after splenectomy in patients with portal hypertension.

AMERICAN SURGEON (2023)

Article Gastroenterology & Hepatology

Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease

Yutaro Ogawa, Takashi Nakahara, Masafumi Ono, Takumi Kawaguchi, Hiroshi Isoda, Akira Hiramatsu, Shinsuke Uchikawa, Hatsue Fujino, Eisuke Murakami, Tomokazu Kawaoka, Masami Yamauchi, Masataka Tsuge, Kensuke Munekage, Tsunehiro Ochi, C. Nelson Hayes, Michio Imamura, Hiroshi Aikata, Hirokazu Takahashi, Takuji Torimura, Kazuaki Chayama

Summary: This study evaluated blood glucose variability in patients with chronic liver disease using a continuous glucose monitoring system (CGMS) and examined the discrepancy between hemoglobin A1c (HbA1c) levels estimated from average blood glucose levels and HbA1c. The results showed that as hepatic functional reserve decreased, average blood glucose and insulin resistance increased while HbA1c decreased. A formula was created to calculate HbA1c without using CGMS. CGMS was useful in assessing accurate glycemic control and detecting hyperglycemia and hypoglycemia. Correction of hepatic functional reserve is necessary for glycemic control in patients with chronic liver disease.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Biotechnology & Applied Microbiology

Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA

Naohiro Kamiya, Takahiko Sugimoto, Hiromi Abe-Chayama, Rie Akiyama, Yasunori Tsuboi, Akira Mogami, Michio Imamura, C. Nelson Hayes, Kazuaki Chayama

Summary: In this study, a robust method was established to untie mature rcDNA into linear DNA, which can be used for quantification and visualization of cccDNA. Precise quantification was achieved by combining the method with plasmid-safe DNase and T5 exonuclease preprocessing and digesting cccDNA with a restriction enzyme. The method was successfully applied to an infection model and demonstrated the possibility of evaluating cccDNA levels accurately.

JOURNAL OF GENERAL VIROLOGY (2022)

Correction Gastroenterology & Hepatology

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs (vol 75, pg 572, 2021)

Heather J. Cordell, James J. Fryett, Kazuko Ueno, Rebecca Darlay, Yoshihiro Aiba, Yuki Hitomi, Minae Kawashima, Nao Nishida, Seik-Soon Khor, Olivier Gervais, Yosuke Kawai, Masao Nagasaki, Katsushi Tokunaga, Ruqi Tang, Yongyong Shi, Zhiqiang Li, Brian D. Juran, Elizabeth J. Atkinson, Alessio Gerussi, Marco Carbone, Rosanna Asselta, Angela Cheung, Mariza de Andrade, Aris Baras, Julie Horowitz, Manuel A. R. Ferreira, Dylan Sun, David E. Jones, Steven Flack, Ann Spicer, Victoria L. Mulcahy, Jinyoung Byun, Younghun Han, Richard N. Sandford, Konstantinos N. Lazaridis, Christopher I. Amos, Gideon M. Hirsch, Michael F. Seldin, Pietro Invernizzi, Katherine A. Siminovitch, Xiong Ma, Minoru Nakamura, George F. Mells

JOURNAL OF HEPATOLOGY (2022)

Article Infectious Diseases

Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody

Haruna Hatooka, Yumi Shimomura, Michio Imamura, Yuji Teraoka, Kei Morio, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Grace Naswa Makokha, Daiki Miki, Masataka Tsuge, Akira Hiramatsu, Hiromi Abe-Chayama, C. Nelson Hayes, Hiroshi Aikata, Shinji Tanaka, Kazuaki Chayama

Summary: The study developed an antibody against preS1 and an ELISA system for measuring serum preS1 levels. PreS1 may serve as a novel tool to predict the need for antiviral therapy in HBeAg-negative HBV-infected patients.

JOURNAL OF INFECTION (2022)

Article Virology

Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection

Toshitada Takemori, Akiko Sugimoto-Ishige, Hironori Nishitsuji, Yushi Futamura, Michishige Harada, Tomomi Kimura-Someya, Takehisa Matsumoto, Teruki Honma, Miho Tanaka, Masami Yaguchi, Kyoichi Isono, Haruhiko Koseki, Hiroyuki Osada, Daiki Miki, Takashi Saito, Takashi Tanaka, Takehiro Fukami, Toshio Goto, Mikako Shirouzu, Kunitada Shimotohno, Kazuaki Chayama

Summary: Entry inhibitors are being developed to enhance the treatment of HBV patients with oral nucleoside/nucleotide analogues (NA). Therapeutic MAbs with neutralizing activity against HBs antigens have been developed to amplify the effectiveness of NA therapy. Targeting NTCP can provide an effective treatment option for patients with chronic hepatitis B, regardless of viral genotype, mutations, and the presence of subviral particles.

JOURNAL OF VIROLOGY (2022)

Review Gastroenterology & Hepatology

Road to elimination of HCV: Clinical challenges in HCV management

C. Nelson Hayes, Michio Imamura, Junko Tanaka, Kazuaki Chayama

Summary: Since its discovery in 1989, the road to a cure for hepatitis C virus (HCV) has been slow, but most patients can now expect to achieve a sustained virological response (SVR). Adverse events are rare or mild, and patients with compensated cirrhosis and other co-morbidities are often eligible for treatment. However, a small number of patients fail to eradicate the virus even after retreatment.

LIVER INTERNATIONAL (2022)

Article Chemistry, Multidisciplinary

Asymmetric total synthesis of four bioactive lignans using donor-acceptor cyclopropanes and bioassay of (-)- and (+)-niranthin against hepatitis B and influenza viruses

Ryotaro Ota, Daichi Karasawa, Mizuki Oshima, Koichi Watashi, Noriko Shimasaki, Yoshinori Nishii

Summary: The asymmetric total synthesis of four lignans and the relationship between enantiomeric structure and anti-viral activity were investigated in this study.

RSC ADVANCES (2022)

Article Biochemistry & Molecular Biology

Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2

Atsushi Hijikata, Clara Shionyu-Mitsuyama, Setsu Nakae, Masafumi Shionyu, Motonori Ota, Shigehiko Kanaya, Takatsugu Hirokawa, Shogo Nakajima, Koichi Watashi, Tsuyoshi Shirai

Summary: This study evaluated the potential of natural analogues of Cepharanthine as anti-coronavirus disease 2019 drugs through molecular docking simulations and cell-based SARS-CoV-2 infection assays. The diphenyl ester moiety of the molecules was suggested as a putative pharmacophore for the CEP analogues according to the docking conformations.

FEBS OPEN BIO (2022)

Article Microbiology

Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action

Masaaki Toyama, Koichi Watashi, Masanori Ikeda, Atsuya Yamashita, Mika Okamoto, Kohji Moriishi, Masamichi Muramatsu, Takaji Wakita, Ashoke Sharon, Masanori Baba

Summary: Novel neplanocin A derivatives have shown potency in inhibiting HBV replication in vitro, reducing HBV RNA levels and antigen production, with a mechanism of action different from clinically approved anti-HBV agents.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Infectious Diseases

SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV

Diane Delobel, Yutaka Furutani, Sumiko Nagoshi, Akihito Tsubota, Akio Miyasaka, Koichi Watashi, Takaji Wakita, Tomokazu Matsuura, Kengo Usui

Summary: SmartAmp-Eprimer binary code (SEB) genotyping is a novel isothermal amplification method that can be used for rapid genotyping of any variable target of interest. By producing specific binary codes, SEB genotyping can accurately identify the 8 main genotypes of HBV.

BMC INFECTIOUS DISEASES (2022)

Article Multidisciplinary Sciences

Structural insights into the HBV receptor and bile acid transporter NTCP

Jae-Hyun Park, Masashi Iwamoto, Ji-Hye Yun, Tomomi Uchikubo-Kamo, Donghwan Son, Zeyu Jin, Hisashi Yoshida, Mio Ohki, Naito Ishimoto, Kenji Mizutani, Mizuki Oshima, Masamichi Muramatsu, Takaji Wakita, Mikako Shirouzu, Kehong Liu, Tomoko Uemura, Norimichi Nomura, So Iwata, Koichi Watashi, Jeremy R. H. Tame, Tomohiro Nishizawa, Weontae Lee, Sam-Yong Park

Summary: Around 250 million people worldwide are infected with hepatitis B virus (HBV), and 15 million of them may also carry hepatitis D virus (HDV), which increases the risk of severe liver disease. The structure of the HBV receptor NTCP has not been solved, but using cryo-electron microscopy, the structure of NTCP bound to an antibody has been determined. Comparison with other related proteins reveals a common mechanism of bile acid transport, and the NTCP structure presents a new pocket for potential drug design.

NATURE (2022)

Article Biotechnology & Applied Microbiology

Isolation, structural determination, and antiviral activities of metabolites from vanitaracin A-producing Talaromyces sp.

Shinji Kamisuki, Hisanobu Shibasaki, Hironobu Murakami, Kan Fujino, Senko Tsukuda, Ikumi Kojima, Koudai Ashikawa, Kazuki Kanno, Tomohiro Ishikawa, Tatsuo Saito, Fumio Sugawara, Koichi Watashi, Kouji Kuramochi

Summary: Three novel compounds were isolated from the culture broth of a vanitaracin A-producing fungus, and their structures were determined. The antiviral activity of these compounds against bovine leukemia virus was evaluated, and vanitaracin B, vanitaraphilone A, and 2-hydroxy-4-(hydroxymethyl)-6-methylbenzaldehyde were found to exhibit activity against the virus. These findings suggest potential candidates for the development of anti-bovine leukemia virus drugs.

JOURNAL OF ANTIBIOTICS (2023)

Review Virology

Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review

Ashraf Elbahrawy, Hassan Atalla, Mohamed Alboraie, Ahmed Alwassief, Ali Madian, Mohammed El Fayoumie, Ashraf A. Tabll, Hussein H. Aly

Summary: Vaccination is the safest and often the only method to protect against infectious diseases. Vaccines have successfully controlled diseases such as smallpox and polio. Hepatitis viruses, including HAV, HBV, HCV, HDV, and HEV, can cause severe liver infections and result in many deaths worldwide. However, effective vaccines are available to prevent hepatitis A and B, and ongoing research is focused on developing vaccines against the other major hepatitis viruses.

VIRUSES-BASEL (2023)

Article Cell Biology

A Combinatorial Code for CPEB-Mediated c-myc Repression

Koichi Ogami, Keima Ogawa, Shoko Sanpei, Fumito Ichikawa, Tsuyoshi Udagawa, Shin-ichi Hoshino

Summary: During early embryonic development, the RNA-binding protein CPEB mediates cytoplasmic polyadenylation and translational activation through a combinatorial code defined by the cytoplasmic polyadenylation element (CPE). In non-neuronal somatic cells, CPEB accelerates deadenylation to repress c-myc mRNA translation through a combination of tandemly arranged consensus (cCPE) and non-consensus (ncCPE) cytoplasmic polyadenylation elements (CPEs). CPEB binds to cCPEs with high affinity and ncCPEs with low affinity, enhancing the recruitment of deadenylases and repression of c-myc mRNAs.

CELLS (2023)

No Data Available